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Summary. The present study analyses the effects of 
hypertension andlor its oral treatment with captopril 
(angiotensine-converting enzyme inhibitor) on the rat 
median eminence (ME) and the posterior lobe of the 
hypophysis (PL). After an immunohistochemical 
reaction using an antibody against arginine-vasopressin, 
we compared by densitometry the amount of vasopressin 
immunoreactive material (vasopressin-ir) of these 
centers in 4 groups of animals: control Wistar Kyoto rats 
(WKY), spontaneously hypertensive rats (SHR), WKY 
rats treated with captopril (WKY-T) and SHR rats also 
treated with the same drug (SHR-T). Captopril was 
administrated at a dosage of 0.1 mglml in. the drinking 
water from the 8th to the 15th weeks. We have found 
that the rats showing the lowest level of vasopressin-ir, 
in both ME and PL, were those from the SHR group, the 
concentration increasing after oral captopril treatment 
(SHR-T), although without reaching the values of WKY 
rats. Then, ACE inhibition by captopril influences 
vasopressin content in brain areas where the hormone is 
concentrated before being released, which supports the 
hypothesis that suggests a central modulatory effect of 
ACE inhibitors, contributing to their therapeutic action 
on hypertension. 
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and antidiuretic effects and its secretion is controlled, at 
least in part, by angiotensinergic imputs that come from 
the subfornical organ (SFO) and reach the para- 
ventricular (PVN) and the supraoptic nucleus (SPO) of 
the hypothalamus (Sgro et al., 1984; Tanaka, 1989). In 
this sense, central administration of angiotensine I1 has 
been reported to stimulate vasopressin release from the 
posterior pituitary gland (Phillips, 1987). 
The spontaneously hypertensive rat (SHR) is the 
most widely studied animal model of genetic hyper- 
tension and it has been described that plasma 
vasopressin concentration is elevated in SHR rats 
(Crofton et al., 1978), and vasopressin contribution in 
the hypertensive process has been examined in different 
animal models of hypertension (Share and Crofton, 
1982). 
Captopril  (an angiotensin-converting enzyme 
inhibitor) is a commonly used drug in the treatment of 
hypertension. The hypotensive effect of captopril could 
be due not only to  the blockade of formation of 
angiotensine I1 in plasma, but also to a local blockade of 
the brain renin-angiotensine system (Dzau, 1987; Fabris 
et al., 1990). 
The aim of the present study was to analyze possible 
changes induced by hypertension and its oral treatment 
with captopril in the amount of vasopressin immuno- 
reactivity in the rat median eminence and pituitary 
posterior lobe. 
Introduction Material and methods 
The hormone vasopressin is primarily synthesized in 
the magnocellular neurons of the hypothalamus, and the 
axons originated in these neurons pass through the 
internal zone of the median eminence (ME) and reach 
the posterior lobe of the hypophysial stalk (PL) (Holmes 
et al., 1991). This hormone is well known for its pressor 
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We have studied 20 male rats,  that were all 
sacrificed at the 15th week of life. Ten control rats 
(Wistar-Kyoto rats, WKY) were divided in two groups: 
one control group of 5 animals (WKY) and another 
group that was treated with oral captopril from the 8th to 
the 15th week of life (WKY-T). Another group of ten 
spontaneously hypertensive rats (SHR) (Leica S/A 
Barcelona, Spain), were also subdivided into a subgroup 
of 5 animals without treatment (SHR) and another 5 
animals (SHR-T) that also received captopril during the 




